Skip to main content

Table 1 Clinical characteristics of the children with T. marneffei

From: Peripheral immune profile of children with Talaromyces marneffei infections: a retrospective analysis of 21 cases

Clinical characteristics Cases (N = 21)
Demographics
 Age (months), median (IQR) 22 (15–34)
 Gender, male (%) 15 (71.43)
 Endemic area, No(%) 21 (100.00)
 Month of diagnosis, median (IQR) 7 (4–9)
Signs and Symptoms
 The interval from onset to addmission (days), median (IQR)a 20 (12–30)
 Fever, No. (%) 20 (95.24)
 Cough, No. (%) 17 (80.95)
 Hepatomegaly, No. (%) 17 (80.95)
 Lymphadenopathy, No. (%) 15 (71.43)
 Splenomegaly, No. (%) 12 (57.14)
 Skin lesion, No. (%) 9 (42.86)
 Dyspnea, No. (%) 9 (42.86)
 Diarrhea, No. (%) 6 (28.57)
 Weight loss, No. (%) 6 (28.57)
 Malnutrition, No. (%) 4 (19.09)
 Ascites, No. (%) 1 (4.76)
 Trachyphonia, No. (%) 1 (4.76)
Significant complication
 Sepsis shock, No. (%) 12 (57.14)
 HLH, No. (%) 11 (52.38)
 ARDS, No. (%) 10 (47.62)
 MODS, No. (%) 9 (42.86)
 DIC, No. (%) 7 (33.33)
Specimens for diagnosis
 Blood, No(%) 19 (90.48)
 BM, No(%) 8 (38.10)
 Lymph nodes, No(%) 4 (19.09)
 Airway mucosal biopsy, No(%) 2 (9.52)
 BALF, No(%) 2 (9.52)
 Ascites, No(%) 1 (4.76)
 Skin, No(%) 1 (4.76)
 Stool, No(%) 1 (4.76)
Antifungal therapy
 The interval from onset to antifungal therapy (days), median (IQR) 25 (17.5–31.5)
 Total, No(%) 19 (90.48)
 Amphotericin B, No(%) 8 (38.10)
 Voriconazole, No(%) 8 (38.10)
 Itraconazole, No(%) 6 (28.57)
 Fluconazole, No(%) 5 (23.81)
 Caspofungin, No(%) 3 (14.29)
Outcomes
 Length of stay (days), median (IQR) 14.5 (4–31)
 Mortality, No. (%) 11 (52.38)
  1. Abbreviation: ARDS acute respiratory distress syndrome, MODS multiple organ dysfunction syndrome, HLH hemophagocytic lymphohistiocytosis, DIC disseminated intravascular coagulation, BM bone marrow, BALF bronchial alveolar lavage fluid, IQR: inter-quartile range
  2. aThe course of disease before addmission at our hospital
\